



Cancer has no borders. Neither do we.

CORPORATE OVERVIEW

BeiGene is a global biotechnology company that is discovering and developing innovative oncology treatments that are more accessible and affordable to cancer patients worldwide.

The company has a commercial presence in more than 65 markets, with products treating various forms of cancer. BeiGene's broad and deep pipeline of novel therapeutics, which it is advancing with its internal capabilities and through partnerships, has the potential to address 80 percent of the world's cancers by incidence.

BeiGene is committed to radically improving access to medicines for patients who need them.

General Company Information	Key Leadership Team Members
<ul style="list-style-type: none">• Founded in 2010• Administrative offices in Basel, Beijing and Cambridge, Mass.• More than 10,000 employees worldwide working on 5 continents• Publicly traded on NASDAQ, Hong Kong Stock Exchange (HKEX) and Shanghai Stock Exchange (SSE)• Achieved \$1.4B in product revenue in 2022• Two internally discovered and developed cornerstone medicines, BRUKINSA® (zanubrutinib) and TEVIMBRA® (tislelizumab)• Global R&D team of 1,100+ oncology scientists, one of the largest such teams in the industry• 60+ pre-clinical programs, the majority with first-in-class potential• ~ 20 industry collaborations• In-house manufacturing capabilities, with U.S. expansion under way	<ul style="list-style-type: none">• John V. Oyler, Co-Founder, Chairman and Chief Executive Officer• Xiaodong Wang, Co-Founder, Chairman of Scientific Advisory Board• Julia Wang, Chief Financial Officer• Graham Hardiman, Senior Vice President, Global Human Resources

To learn more about BeiGene, please visit <https://www.beigene.com/>.